Elanco Animal Health Incorporated research snapshot
ELAN AI stock analysis reads Elanco Animal Health as a global pet and farm animal health company whose innovation-led recovery gained momentum through the first half of 2026. As of the July 31, 2026 close at $26.37, the stock has a verified market cap near $13.17 billion on about 499.45 million shares, and it has risen roughly 87% over the trailing twelve months. Trailing GAAP results still show a loss, with TTM EPS near -$0.49, while raised 2026 guidance, first-quarter adjusted EPS of $0.40, product launches such as Zenrelia, Credelio Quattro, and Befrena, and debt reduction are the bull case drivers. The ELAN AI stock forecast uses scenario ranges rather than a single price call because leverage, competition with Zoetis and other animal health peers, product uptake, and multiple expansion after a strong run can change outcomes quickly. Q2 2026 earnings are scheduled for August 5, 2026.
Current price
$26.37
Market cap
$13.17 billion verified market cap
AI score
67 / 100
Rating
Innovation-led animal health recovery with a more demanding valuation and Q2 2026 results due August 5
Trend status
Constructive, trading above the 50-day and 200-day moving averages near the top of the 52-week range
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Elanco sells parasiticides, vaccines, therapeutics, and other animal health products to pet owners, veterinarians, and livestock producers worldwide. TTM revenue is about $4.89 billion, up 10.5% year over year. | High |
| Moat | Brand reach, veterinary relationships, regulatory know-how, and a broader product portfolio support the franchise, but competition from Zoetis and other animal health companies keeps pricing and share contested. | Medium |
| Management | CEO Jeff Simmons has steered the post-spin and Bayer Animal Health integration phase toward innovation launches, raised full-year 2026 guidance, and set a year-end net leverage target of 3.0x to 3.2x from 3.5x at Q1 2026. | Medium-high |
| Financial trend | FY2025 revenue was $4.715 billion, up about 6% year over year, while reported net loss was $232 million. Q1 2026 revenue of $1,371 million rose 15% with adjusted EPS of $0.40 and adjusted EBITDA of $334 million. | High |
| Valuation | At $26.37, ELAN screens near 2.03x book value, about 2.69x sales, 41.8x free cash flow, and 24.3x forward earnings, while TTM GAAP PE is not meaningful because EPS is negative. | High |
| Technical trend | The stock is above the 50-day average near $24.40 and the 200-day average near $23.46, with RSI near 63.11 and a 52-week range of $13.39 to $27.72. | Medium |
| Risk level | Main risks are elevated leverage, product launch underperformance, competition, farm animal demand swings, short interest near 7.17% of shares, an after-hours reading near $25.19 after the July 31 close, and continued GAAP losses. | Medium-high |
| AI confidence | Descriptive confidence is high because key figures were cross-checked. Return confidence is lower because adjusted-to-GAAP conversion, competitive product uptake, and the sustainability of the 87% run remain uncertain. | High data confidence |
| Investment certainty | ELAN has improving operational momentum, but the price after a large run needs sustained innovation revenue, leverage progress, and cleaner earnings quality to create a wide margin of safety. | Medium |
ELAN AI stock forecast
The ELAN AI stock forecast is scenario-based because trailing GAAP EPS is negative and the equity story depends on adjusted earnings growth, product launches, and leverage reduction. Using the $26.37 price reference, a $1.06 adjusted EPS base near the raised 2026 guidance midpoint, and an audited three-year model, the mechanical outcomes are about $43.50 in a bullish case, $29.80 in a base case, and $17.20 in a bearish case before any dividend, which Elanco does not currently pay.
$38 to $46 before dividends
More likely if innovation revenue tracks toward the $1.2 billion 2026 target, Zenrelia, Credelio Quattro, and Befrena take share, farm animal demand stays strong, net leverage falls toward 3.0x to 3.2x and then lower, and the market keeps re-rating adjusted earnings toward the mid-20s PE range.
$27 to $32 before dividends
More likely if revenue grows mid- to high-single digits, adjusted EPS stays near company guidance of $1.03 to $1.09 for 2026 with modest growth after that, and investors keep valuing ELAN near a high-teens to low-20s earnings multiple.
$15 to $19 before dividends
More likely if product launches disappoint, farm animal demand softens, competition forces pricing pressure, leverage stays elevated, free cash flow weakens, the stock gives back part of its 87% gain, or the market compresses the multiple toward distressed animal health levels.
ELAN AI technical analysis
ELAN AI technical analysis is constructive but extended as of the August 2, 2026 data cutoff. StockAnalysis showed a July 31 close of $26.37, a 50-day moving average near $24.40, a 200-day moving average near $23.46, RSI near 63.11, 20-day average volume near 4.55 million shares, and a 52-week range of $13.39 to $27.72. An after-hours print near $25.19 was shown on July 31, so traders should confirm live price before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $26.37 | StockAnalysis listed the July 31, 2026 close at $26.37 after a day range of $25.77 to $26.47, near the top of the 52-week range. |
| Immediate support | $24.00 to $24.50 | This area brackets the 50-day average near $24.40 and is the first trend-support zone to watch on a pullback. |
| Deeper support | $23.00 to $23.50 | This zone sits near the 200-day average near $23.46, where prior consolidation after the 2025 rebound could reassert itself. |
| Near resistance | $26.50 to $27.00 | This is the next reaction zone below the recent high where short-term buyers need follow-through volume. |
| Upper resistance | $27.50 to $28.00 | This range sits near the 52-week high of $27.72 and is the key breakout area for the current recovery swing. |
| Moving averages | 50-day near $24.40, 200-day near $23.46 | A close above both moving averages keeps the recovery intact, while a break below both would weaken momentum quickly. |
| Momentum | RSI near 63.11 | Momentum is constructive but no longer oversold, so a further push needs volume confirmation and earnings support. |
| Volume | 20-day average near 4.55 million shares | Volume confirmation matters around the August 5, 2026 earnings, product updates, and leverage commentary because ELAN can move sharply on growth and debt news. |
| Volatility | Watch August 5, 2026 earnings and short interest | The next earnings update, innovation revenue progress, short interest near 7.17% of shares, and an after-hours move near $25.19 can amplify swings around key levels. |
| Invalidation | Close below $24.00, then below $23.00 | A sustained break below the clustered moving averages weakens the recovery. A break toward $23.00 would challenge the larger rebound setup. |
ELAN AI trading strategy
The ELAN AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with innovation revenue, pet and farm mix, competitive product uptake, free cash flow, net leverage, and GAAP versus adjusted earnings quality after a large price run.
Watch for ELAN to hold above the $24.00 to $24.50 support area and press through $26.50 to $27.00 toward the $27.72 high with improving innovation revenue, stable adjusted margins, and no new leverage or competitive shock.
A failed breakout followed by a close below $24.00 should reduce trend confidence, especially if management signals weaker product uptake or slower debt reduction.
If ELAN pulls back toward $24 or $23 without a permanent earnings reset, compare the lower price with free cash flow per share near $0.63, net leverage progress, and the durability of raised adjusted EPS guidance.
Do not treat a pullback as automatically attractive if leverage rises again, free cash flow weakens, competition erodes the innovation pipeline thesis, or the stock breaks the moving-average cluster on earnings.
Track pet health growth, farm animal demand, Zenrelia, Credelio Quattro, and Befrena launch metrics, adjusted EBITDA margin, free cash flow conversion, net debt, net leverage ratio, short interest, and the gap between GAAP and adjusted results.
Position sizing should reflect that animal health stocks can look extended after a large run and can reprice quickly if leverage, competitive pricing, or product delays change the story.
Investment research summary
Customers pay Elanco because pet owners, veterinarians, and livestock producers need parasiticides, vaccines, therapeutics, and related animal health products that protect animal welfare and farm productivity, and the company is converting innovation launches into revenue growth.
The moat comes from brand portfolio breadth, veterinary relationships, regulatory expertise, manufacturing scale, and an expanding innovation stack. The moat is real but not unassailable, especially against Zoetis and other global animal health competitors.
The thesis fails if new products underdeliver, competition compresses pricing, farm animal demand weakens, leverage stays too high for too long, or free cash flow cannot convert adjusted profits into durable balance-sheet repair.
Jeff Simmons has focused the company on innovation-led growth and debt paydown after the Bayer Animal Health integration, and raised full-year 2026 guidance. The current management test is proving that growth can coexist with cleaner earnings quality and lower net leverage.
Animal health sits inside multi-year demand for pet medicalization, livestock productivity, vaccines, and dermatology or parasiticide innovation. The offset is competitive intensity and the fact that farm animal cycles can still create earnings volatility.
At $26.37, ELAN is no longer priced like a distressed asset, and after an 87% twelve-month gain the margin of safety is thinner. It improves if innovation revenue lands, leverage falls toward or below 3.0x, and free cash flow stays positive while multiples remain reasonable.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $26.37 July 31, 2026 close | StockAnalysis ELAN quote | August 2, 2026 |
| Market cap and shares | $13.17 billion market cap, 499.45 million shares, verified as $26.37 x 499,450,000 shares with 0.00% deviation | StockAnalysis statistics and financial_rigor.py | August 2, 2026 |
| TTM revenue | $4.89 billion, up 10.5% year over year | StockAnalysis financials | August 2, 2026 |
| FY2025 revenue | $4.715 billion, up 6.22% year over year | StockAnalysis financials, Macrotrends, and Elanco FY2025 results | August 2, 2026 |
| FY2025 net income | Reported net loss of $232 million | StockAnalysis financials and Elanco FY2025 results | August 2, 2026 |
| Q1 2026 operating snapshot | Revenue $1,371 million, adjusted EPS $0.40, adjusted EBITDA $334 million, net leverage 3.5x | Elanco Q1 2026 results | August 2, 2026 |
| FY2026 guidance | Revenue $5,010 million to $5,085 million, adjusted EPS $1.03 to $1.09, adjusted EBITDA $975 million to $1,005 million, year-end net leverage 3.0x to 3.2x, innovation target $1.2 billion | Elanco Q1 2026 results guidance raise | August 2, 2026 |
| Cash and debt | About $428 million cash and $3.99 billion total debt on StockAnalysis; company net debt near $3.34 billion at Q1 2026 | StockAnalysis balance sheet and Elanco Q1 2026 results | August 2, 2026 |
| Free cash flow | TTM free cash flow about $315 million, or $0.63 per share | StockAnalysis cash flow and statistics | August 2, 2026 |
| Valuation ratios | 2.03x P/B, about 2.69x sales, 41.8x P/FCF, forward PE near 24.3; TTM PE not meaningful on -$0.49 EPS | financial_rigor.py calculation from StockAnalysis inputs | August 2, 2026 |
| Technical levels | 50-day MA near $24.40, 200-day MA near $23.46, RSI near 63.11, 52-week range $13.39 to $27.72, 20-day average volume near 4.55 million shares | StockAnalysis ELAN technical data | August 2, 2026 |
| Short interest | 35.82 million shares, about 7.17% of shares outstanding | StockAnalysis statistics | August 2, 2026 |
| Analyst consensus | Strong Buy from 17 analysts with an average price target near $30.07, range $26 to $32 | StockAnalysis forecast and analyst ratings | August 2, 2026 |
| CEO | Jeff Simmons, President and CEO | Elanco investor communications | August 2, 2026 |
This ELAN AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a guarantee of future returns. Forecast scenarios are based on available public data as of August 2, 2026 and may be wrong if product launches, leverage, competition, valuation multiples, or market conditions change. Confirm current prices and confirm the reason for any after-hours move before trading.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
